FBRX250221C2500
- 0.05
- 0.000.00%
Forte Biosciences Newsroom
Express News | Forte Biosciences Files for Offer & Resale From Time to Time of up to 9.5 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Express News | Chardan Capital Maintains Buy on Forte Biosciences, Maintains $64 Price Target
Forte Biosciences to Host R&D Day December 3, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results
Quantum-Si QSI SKYT & NVDA Deal; Forte Biosciences FBRX Equity Financing
Trending Stocks Today | Forte Biosciences Surges 121.22%
Forte Biosciences More Than Doubles on $53M Private Placement
Nasdaq Tumbles Over 100 Points; TJX Earnings Top Views
US Stocks Mostly Lower; Target Posts Downbeat Earnings
Express News | Forte Biosciences Shares Halted On Circuit Breaker To The Downside, Stock Now Up 61.9%
Forte Biosciences Secures $53M In Oversubscribed Private Placement To Advance FB102 Clinical Programs Across Autoimmune Indications, With Key Data Readouts Expected In 2025
Express News | Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Chardan Boosts Price Target on Forte Biosciences to $64 From $3, Keeps Buy Rating
Forte Biosciences | 8-K: FORTE BIOSCIENCES, INC. ANNOUNCES THIRD QUARTER 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Forte Biosciences | 10-Q: Q3 2024 Earnings Report
Press Release: Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
Forte Biosciences 3Q Loss/Shr $4.54 >FBRX
12 Health Care Stocks Moving In Thursday's Intraday Session
Forte Biosciences Welcomes New Directors Amidst Strategic Changes